Participant flow

Erlotinib Hydrochloride or Crizotinib and Chemoradiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer · Source last updated 2019-08-05

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups

1. description

   Induction erlotinib for 12 weeks followed by chemotherapy (either cisplatin/etoposide or paclitaxel/carboplatin) and radiation therapy. Patients who have had no response (partial or complete) after 6 weeks of induction therapy start chemoradiation therapy immediately.

   id

   FG000

   title

   EGFR: Erlotinib

2. description

   Chemotherapy (either cisplatin/etoposide or paclitaxel/carboplatin) and radiation therapy.

   id

   FG001

   title

   EGFR: No Erlotinib

3. description

   Induction crizotinib for 12 weeks followed by chemotherapy (either cisplatin/etoposide or paclitaxel/carboplatin) and radiation therapy. Patients who have had no response (partial or complete) after 6 weeks of induction therapy start chemoradiation therapy immediately.

   id

   FG002

   title

   ALK: Crizotinib

4. description

   Chemotherapy (either cisplatin/etoposide or paclitaxel/carboplatin) and radiation therapy.

   id

   FG003

   title

   ALK: No Crizotinib

periods

1. drop Withdraws

   1. reasons

      1. group Id

         FG000

         num Subjects

         2

      2. group Id

         FG001

         num Subjects

         2

      3. group Id

         FG002

         num Subjects

         0

      4. group Id

         FG003

         num Subjects

         1

      type

      Protocol Violation

   2. reasons

      1. group Id

         FG000

         num Subjects

         0

      2. group Id

         FG001

         num Subjects

         0

      3. group Id

         FG002

         num Subjects

         0

      4. group Id

         FG003

         num Subjects

         3

      type

      Withdrawal by Subject

   milestones

   1. achievements

      1. group Id

         FG000

         num Subjects

         16

      2. group Id

         FG001

         num Subjects

         23

      3. group Id

         FG002

         num Subjects

         9

      4. group Id

         FG003

         num Subjects

         11

      type

      STARTED

   2. achievements

      1. group Id

         FG000

         num Subjects

         14

      2. group Id

         FG001

         num Subjects

         21

      3. group Id

         FG002

         num Subjects

         9

      4. group Id

         FG003

         num Subjects

         7

      type

      Eligible

   3. achievements

      1. group Id

         FG000

         num Subjects

         10

      2. group Id

         FG001

         num Subjects

         15

      3. group Id

         FG002

         num Subjects

         6

      4. group Id

         FG003

         num Subjects

         4

      type

      Eligible With Disease Assessment

   4. achievements

      1. group Id

         FG000

         num Subjects

         14

      2. group Id

         FG001

         num Subjects

         20

      3. group Id

         FG002

         num Subjects

         9

      4. group Id

         FG003

         num Subjects

         7

      type

      Eligible and Started Study Treatment

   5. achievements

      1. group Id

         FG000

         num Subjects

         14

      2. group Id

         FG001

         num Subjects

         21

      3. group Id

         FG002

         num Subjects

         9

      4. group Id

         FG003

         num Subjects

         7

      comment

      Subjects contributing any data to results are considered to have completed the study

      type

      COMPLETED

   6. achievements

      1. group Id

         FG000

         num Subjects

         2

      2. group Id

         FG001

         num Subjects

         2

      3. group Id

         FG002

         num Subjects

         0

      4. group Id

         FG003

         num Subjects

         4

      type

      NOT COMPLETED

   title

   Overall Study

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice